Notice of Extraordinary General Meeting 6 June 2016
(Oslo, Norway, 13 May 2016) An Extraordinary General Meeting of Bionor Pharma ASA will be held on Monday 6 June 2016 at 15:00 hours at Kronprinsesse Märthas plass 1, Oslo, Norway, at the meeting room on the 9th floor.
At the Annual General Meeting on 22 April 2016, a number of the proposed resolutions were not approved. The new Board has completed a renewed evaluation of the proposals made, but not resolved at the Annual General Meeting. Following the renewed evaluation, the Board has unanimously resolved to call an extraordinary general meeting.
The notice of the Extraordinary General Meeting on 6 June 2016 is attached hereto and includes detailed registration and proxy instructions.
All relevant documents and link to online registration of attendance and advance voting can be found on www.bionorpharma.com.
Please note that to attend the Extraordinary General Meeting, attendants must be registered shareholders five working days prior to the meeting – 30 May 2016.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Cecilie Grue, Director Legal Affairs, +47 99162486, firstname.lastname@example.org
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, email@example.com
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.